---
document_datetime: 2023-09-21 17:10:58
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/zometa-epar-procedural-steps-taken-authorisation_en.pdf
document_name: zometa-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.382487
conversion_datetime: 2025-12-24 01:52:12.384336
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  company  Novartis  Europharm  Limited  submitted  on  21  December  1999  an  application  for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Zometa, through the centralised procedure. After agreement by the CPMP on 24 June 1999, this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993, as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur: Dr. Jens Ersb√∏ll Co-Rapporteur: Prof. Silvio Garattini

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 21 January 2000.
- The Rapporteur's first assessment report was circulated to all CPMP  Members on 11 April 2000.  The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP Members on 31 March 2000.
- During the meeting on 23-25 May 2000 the CPMP agreed on the consolidated list of questions to be sent to the company. The final consolidated list of questions was sent to the company on 26 May 2000.
- During  the  meeting  on  23-25  May  2000  the  CPMP  decided  to  request  an  inspection  of  the manufacturing sites.
- The  inspection  was  carried  out  between  8-11 August  2000  at  the  manufacturing  sites  of  the finished product and the packaging site. The summary report of the inspection was issued on 12 September 2000.
- The company submitted the responses to the consolidated list of questions on 20 October 2000.
- The Rapporteur circulated the response assessment report on the company's responses to the list of questions to all CPMP Members on 24 November 2000.
- During  the  meeting  on  12-14  December  2000  the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Zometa on 14 December 2000.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 20 March 2001.